Clinical Trials Sponsored by Symyoo

Total 40 results

Symyoo

Completed

Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation

Premature Ejaculation

Korea, Republic of
Symyoo

Completed

Trial of PED-1 in Male Patients With Premature Ejaculation

Premature Ejaculation

Korea, Republic of
Genexine, Inc.
Symyoo

Completed

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

Total Thyroidectomy | Near-total Thyroidectomy

Korea, Republic of
CTC Bio, Inc.
Symyoo

Completed

Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy

Colon Disease | Colonoscopy Preparation

Korea, Republic of
CTC Bio, Inc.
Symyoo

Completed

Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males

Healthy

Korea, Republic of
CTC Bio, Inc.
Symyoo

Unknown

A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation

Premature Ejaculation

Korea, Republic of
Green Cross Corporation
Symyoo

Completed

GCPGC in Chemotherapy-induced Neutropenia

Chemotherapy Induced Neutropenia

Korea, Republic of
Green Cross Corporation
Symyoo

Terminated

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

Septic Shock | Severe Sepsis

Korea, Republic of
Green Cross Corporation
Symyoo

Completed

To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin

Healthy Volunteer
SymBio Pharmaceuticals

Recruiting

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

BK Virus Infection | Kidney Transplantation | Nephropathy

Australia, Japan
SymBio Pharmaceuticals

Completed

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Lymphoma, B-cell, Diffuse

Japan
SymBio Pharmaceuticals

Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
SymBio Pharmaceuticals

Completed

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Drug Drug Interaction

Japan
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Japan
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Terminated

Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

Postoperative Pain

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Low-grade B Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated

Japan
SymBio Pharmaceuticals

Recruiting

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection (ATHENA)

Adenovirus Infection

United States
SymBio Pharmaceuticals

Completed

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Diffuse Large B Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Japan
SymBio Pharmaceuticals

Completed

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Radiotherapy-induced Nausea and Vomiting (RINV)

Japan
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, Diffuse

Japan, Korea, Republic of
SymBio Pharmaceuticals

Terminated

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Multiple Myeloma

Japan
BioMendics, LLC
Symbio, LLC

Completed

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

Wound Healing

United States
Amneal Pharmaceuticals, LLC
Symbio, LLC

Completed

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

Uncomplicated Urinary Tract Infections

United States
Sofregen Medical, Inc.
Symbio, LLC

Active, not recruiting

Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

Nasolabial Fold | Cheek Augmentation

United States
Prollenium Medical Technologies Inc.
Symbio, LLC

Completed

A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation

Lip Augmentation

United States
Prollenium Medical Technologies Inc.
Symbio, LLC

Terminated

A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation

Lip Augmentation

United States
Prollenium Medical Technologies Inc.
Symbio, LLC

Completed

Safety and Effectiveness of PN40082 for Lip Augmentation

Lip Augmentation

United States
Ho Cheol Shin, M.D., Ph.D.
Green Cross Corporation; Ajou University School of Medicine; Symyoo

Completed

Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients

Chronic Fatigue Syndrome | Idiopathic Chronic Fatigue

Korea, Republic of
DeviceFarm, Inc.
Symbio, LLC; Center for Dermatology Clinical Research, Inc.

Completed

Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)

Onychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton Mentagrophytes

United States

3

Subscribe